149 related articles for article (PubMed ID: 31341033)
1. Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining
Peyser BD; Hermone A; Salamoun JM; Burnett JC; Hollingshead MG; McGrath CF; Gussio R; Wipf P
Mol Cancer Ther; 2019 Oct; 18(10):1765-1774. PubMed ID: 31341033
[TBL] [Abstract][Full Text] [Related]
2. Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.
Zhan Y; Zhou X; Peuget S; Singh M; Peyser BD; Fan Z; Selivanova G
Mol Cancer Ther; 2022 Oct; 21(10):1524-1534. PubMed ID: 35877475
[TBL] [Abstract][Full Text] [Related]
3. Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway.
Lin J; Jin X; Bu Y; Cao D; Zhang N; Li S; Sun Q; Tan C; Gao C; Jiang Y
Org Biomol Chem; 2012 Dec; 10(48):9734-46. PubMed ID: 23151607
[TBL] [Abstract][Full Text] [Related]
4. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
5. Identification and targeting of selective vulnerability rendered by tamoxifen resistance.
Singh M; Zhou X; Chen X; Santos GS; Peuget S; Cheng Q; Rihani A; Arnér ESJ; Hartman J; Selivanova G
Breast Cancer Res; 2020 Jul; 22(1):80. PubMed ID: 32727562
[TBL] [Abstract][Full Text] [Related]
6. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
7. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.
Gottlieb A; Althoff K; Grunewald L; Thor T; Odersky A; Schulte M; Deubzer HE; Heukamp L; Eggert A; Schramm A; Schulte JH; Künkele A
Oncotarget; 2017 Apr; 8(17):27882-27891. PubMed ID: 28427187
[TBL] [Abstract][Full Text] [Related]
8. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.
Nieves-Neira W; Rivera MI; Kohlhagen G; Hursey ML; Pourquier P; Sausville EA; Pommier Y
Mol Pharmacol; 1999 Sep; 56(3):478-84. PubMed ID: 10462535
[TBL] [Abstract][Full Text] [Related]
9. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
[TBL] [Abstract][Full Text] [Related]
10. Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380.
Huang X; Cao M; Wang L; Wu S; Liu X; Li H; Zhang H; Wang RY; Sun X; Wei C; Baggerly KA; Roth JA; Wang M; Swisher SG; Fang B
Oncotarget; 2015 Jan; 6(1):345-54. PubMed ID: 25514600
[TBL] [Abstract][Full Text] [Related]
11. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses.
Saha MN; Jiang H; Mukai A; Chang H
Mol Cancer Ther; 2010 Nov; 9(11):3041-51. PubMed ID: 21062913
[TBL] [Abstract][Full Text] [Related]
12. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design and synthesis of novel furan-diketopiperazine-type derivatives as potent microtubule inhibitors for treating cancer.
Ding Z; Li F; Zhong C; Li F; Liu Y; Wang S; Zhao J; Li W
Bioorg Med Chem; 2020 May; 28(10):115435. PubMed ID: 32278711
[TBL] [Abstract][Full Text] [Related]
14. Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance.
Bu Y; Cai G; Shen Y; Huang C; Zeng X; Cao Y; Cai C; Wang Y; Huang D; Liao DF; Cao D
Cancer Lett; 2016 Dec; 383(2):261-271. PubMed ID: 27721021
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.
Yang J; Ahmed A; Poon E; Perusinghe N; de Haven Brandon A; Box G; Valenti M; Eccles S; Rouschop K; Wouters B; Ashcroft M
Mol Cell Biol; 2009 Apr; 29(8):2243-53. PubMed ID: 19223463
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.
Kudou N; Taniguchi A; Sugimoto K; Matsuya Y; Kawasaki M; Toyooka N; Miyoshi C; Awale S; Dibwe DF; Esumi H; Kadota S; Tezuka Y
Eur J Med Chem; 2013 Feb; 60():76-88. PubMed ID: 23287053
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Enzyme Sulfotransferase 1A1 Is the Trigger for N-Benzyl Indole Carbinol Tumor Growth Suppression.
Rothman DM; Gao X; George E; Rasmusson T; Bhatia D; Alimov I; Wang L; Kamel A; Hatsis P; Feng Y; Tutter A; Michaud G; McDonald E; Venkatesan K; Farley D; Digan ME; Ni Y; Harbinski F; Gunduz M; Wilson CJ; Buckler A; Labow M; Tallarico J; Myer VE; Porter JA; Wang S
Chem Biol; 2015 Sep; 22(9):1228-37. PubMed ID: 26364931
[TBL] [Abstract][Full Text] [Related]
18. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
19. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
Espinoza-Fonseca LM
Theor Biol Med Model; 2005 Sep; 2():38. PubMed ID: 16174299
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition.
Guo W; Wu S; Wang L; Wei X; Liu X; Wang J; Lu Z; Hollingshead M; Fang B
PLoS One; 2011; 6(12):e28487. PubMed ID: 22174819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
